January 7, 2016 – By Matthew Driskill in FiercePharmaAsia The Chinese government is expected to announce a precision medicine initiative in March that is expected to be over $9 Billion over 15 years – far beyond the $215 million U.S. plan announced last year. With that funding, many research projects around genome sequencing and specifically […]
All posts by: Anke
PharmaTimes on 17. November 2015 The National Institute for Health and Care Excellence has published final draft guidance rejecting the use of Kadcyla (trastuzumab-emtansine) for patients as the first and only targeted chemotherapy for secondary HER2-positive breast cancer, because of its high price tag – around £90,000 per course (list price). Full article at PharmaTimes: […]
PharmaTimes on 18. Nov. 2015 Merck Serono’s Erbitux and Amgen’s Vectibix cannot be used as first line therapies alongside chemotherapy for RAS wild-type metastatic colorectal cancer. While recognising their clinical effectiveness, the Institute’s Expert Review group concluded that even if they were provided for free they would still not be cost-effective, as the methodology used […]
18. Nov. 2015 in PharmaTimes The National Institute for Health and Care Excellence has turned down Amgen’s Repatha – the world’s first approved PCSK9 inhibitor – as an option for people with high cholesterol and mixed dyslipidaemia. Key reasons for the negative decision were: (1) no long-term outcomes data and thus, the question of whether […]
FiercePharma, 22. Apr. 2015 Japan’s health regulators are in the midst of deciding how to conduct cost-effective assessments for drugs and medical devices with under the Central Social Insurance Medical Council, better known as Chuikyo. The Government of Prime Minister Shinzo Abe adopted a plan last year that stipulates the trial rollout of cost-effective assessments […]
There is a lot of talk in industry, among the public, or among payers about VALUE related to health services or products. But do they mean the same, when they talk about it. Read a recent (March 2015) assay by Ed Schoonveld in ‘PharmExec.com’ : http://www.pharmexec.com/can-payers-and-drug-industry-agree-real-value?
China’s government issued new guidelines to centralize hospital procurements of all medicines by requiring them to obtain them only through provincial governments. The aim of the change was to reduce unnecessary expenses and safeguard against physician kickbacks. The guideline issued by the China cabinet, its State Council, excluded traditional Chinese medicine from the new requirements. […]
FierceHealthPayer, Feb 25, 2015 By Dina Overland Although almost 25 state programs employ higher copays for emergency department visits in an effort to decrease ED use, charging more when Medicaid recipients go to the ED may not be effective, reported Stateline. At least one multistate study determined that charging higher copays doesn’t necessarily lower ED […]
Fierce Pharma, February 19, 2015 | By Eric Palmer Drugmakers are often at odds with the National Institute for Health and Care Excellence (NICE) in England, saying it is stingy in what it will approve as payments for their best new treatments. But the industry and the gatekeeper have pulled together in defending against a […]
Wisconsin State Journal, Feb 18, 2015 Epic Systems Corp. is about to launch its own app store — much like Apple’s App Store — opening the door for outside companies to create applications that will work with Epic’s widely used electronic health records systems. Mark Bakken, co-founder and former chief executive of Nordic Consulting, the […]